Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development Ailux, a subsidiary of XtalPi, is collaborating with Eli Lilly to enhance bispecific antibody development using AI technology for novel therapies.

Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development #China #Shanghai #Eli_Lilly #XtalPi #Ailux

Ailux Partners with Lilly to Revolutionize Bispecific Antibody Development Ailux, a subsidiary of XtalPi, collaborates with Lilly to enhance bispecific antibody discovery, potentially worth $345 million in total.

Ailux Partners with Lilly to Revolutionize Bispecific Antibody Development #Shanghai #USA #Lilly #XtalPi #Ailux